Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial

This publication has 12 references indexed in Scilit:

• Chronic Administration of Single-Agent Paclitaxel in Gynecologic Malignancies
  Gynecologic Oncology, 2001
• Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer
  Journal of Clinical Oncology, 2000
• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials
  Journal of Clinical Oncology, 2000
• Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2000
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Paclitaxel (Taxol)
  New England Journal of Medicine, 1995
• Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
  Published by American Medical Association (AMA) ,1995
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
  Journal of Clinical Oncology, 1989
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983